Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%76 Operating Cash Flow per Share is $0.67 as of Dec. 2025. GuruFocus rates SHTDF with a GF Score™ of 76/100 and a GF Value™ of $2.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 80 Medical Distribution companies, Sinopharm Group Co ranks worse than 72.5% on this metric.
Sinopharm Group Co's operating cash flow per share for the
six
months ended in Dec. 2025 was $2.20.
Sinopharm Group Co's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.67.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Sinopharm Group Co was 26.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -12.60% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Sinopharm Group Co's Operating Cash Flow per Share or its related term are showing as below:
SHTDF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -37.9 Med: 21.9 Max: 72
Current: -12.6
During the past 13 years, Sinopharm Group Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.00% per year. The lowest was -37.90% per year. And the median was 21.90% per year.
SHTDF's 3-Year OCF Growth Rate is ranked worse than 72.5% of 80
companies
in the Medical Distribution industry
Industry Median: 10.55
vs SHTDF: -12.60
Sinopharm Group Co Operating Cash Flow per Share Related Terms
Sinopharm Group Co Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Operating Cash Flow per Share Chart
SHTDF vs MCK, COR, CAH: Operating Cash Flow per Share Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Operating-Cash-Flow vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.67 mean?
Sinopharm Group Co (SHTDF) has a Operating Cash Flow per Share of $0.67 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #58 out of 80 companies in the Medical Distribution industry, placing it in the top 72.5%.
Is Sinopharm Group Co's Operating Cash Flow per Share too high?
Sinopharm Group Co's current Operating Cash Flow per Share is $0.67. The Medical Distribution industry median Operating Cash Flow per Share is 10.55. Sinopharm Group Co's value of $0.67 is 93.6% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #58 out of 80 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Operating Cash Flow per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #58 out of 80 companies for Operating Cash Flow per Share. This places Sinopharm Group Co in the lower half of its industry. The industry median Operating Cash Flow per Share is 10.55. Sinopharm Group Co's value of $0.67 is 93.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Distribution company?
The median Operating Cash Flow per Share among Medical Distribution companies is 10.55, based on 80 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Operating Cash Flow per Share of $0.67 is 93.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Operating Cash Flow per Share is 10.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Operating Cash Flow per Share is $0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.69, compared to a current price of $2.13 — trading 20.7% below its estimated fair value. The current Operating Cash Flow per Share is $0.67 and 93.6% below the Medical Distribution industry median of 10.55. Sinopharm Group Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Operating Cash Flow per Share is $0.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 20.7% below its estimated GF Value™ of $2.69.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Operating Cash Flow per Share: $0.67
GF Value™: $2.69 vs. price of $2.13 (20.7% below fair value)
Industry Position: 93.6% below the Medical Distribution median (#58 of 80)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
76GF Score
Get the complete analysis for SHTDF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
